Knight Therapeutics Inc. provided revenue guidance for the fiscal year 2024. For the period, the company expected to generate revenues between $335 million to $350 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.14 CAD | +0.66% | +0.66% | +18.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.30% | 455M | |
+11.98% | 9.08B | |
-10.76% | 5.06B | |
+53.60% | 4.85B | |
+7.56% | 3.85B | |
+14.09% | 2.37B | |
-21.42% | 2.36B | |
+25.03% | 2.27B | |
-30.36% | 2.22B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024